Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438563 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP4Z1MAOBGAAALDH1A1 | |
| SCHEMBL24207172 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP4Z1MAOBCYP1A2GAA | |
| SCHEMBL6893223 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP4Z1MAOBGAAALDH1A1 | |
| SCHEMBL24207037 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP4Z1MAOBGAAALDH1A1 | |
| SCHEMBL9606643 | 0.82 | ALDH1A1 (0.45) | SMN1; SMN2CYP4Z1MAOBGAAALDH1A1 | |
| SCHEMBL2381215 | 0.80 | MAOB (0.44) | SMN1; SMN2CYP4Z1MAOBCYP1A2GAA | |
| SCHEMBL2131830 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP4Z1CYP1A2GAAALDH1A1 | |
| SCHEMBL5627469 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP4Z1CYP1A2GAAALDH1A1 | |
| SCHEMBL4278414 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2CYP4Z1MAOBGAAALDH1A1 | |
| SCHEMBL11147975 | 0.79 | THRB (0.46) | SMN1; SMN2CYP4Z1GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791426-A | (R) -glutarimide CRBN ligands and methods of use | 百济神州有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240131167-A1 | EGFR Degraders and Associated Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-04-25 | — | — | US | disclosed |
| CN-117616021-A | (R) -glutarimide CRBN ligands and methods of use | 百济神州有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117222637-A | EGFR degrading agents and related methods of use | 百济神州有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-8252833-B2 | Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-08-28 | — | — | US | disclosed |
| EP-2457897-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| CN-101415678-A | Benzo (F) isoindol-2-ylphenylacetic acid derivatives as EP4Receptor agonists | GLAXO GROUP LTD (GB) | 2009-04-22 | — | — | CN | disclosed |
| US-20080167377-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| WO-2008071736-A1 | BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007088190-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167377-A1 | Novel compounds | F12, C1R, MRGPRX1 | SMN1; SMN2 979/4885CYP4Z1 2203/4885MAOB 1261/4885 |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | SMN1; SMN2 4590/4885CYP4Z1 3711/4885MAOB 2741/4885 |
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER2 | SMN1; SMN2 3750/4885CYP4Z1 957/4885MAOB 1511/4885 |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | PTGER4, PTGER1, PTGER3 | SMN1; SMN2 2638/4885CYP4Z1 1625/4885MAOB 1430/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | SMN1; SMN2 2282/4885CYP4Z1 2157/4885MAOB 2098/4885 |
| US-20240131167-A1 | EGFR Degraders and Associated Methods of Use | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4063/4885CYP4Z1 3620/4885MAOB 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.